Zacks Small Cap Analysis – PLX: Revisiting the Thesis – Tech Journal

By John Vandermosten, CFA

NYSE:PLX

READ THE FULL PLX RESEARCH REPORT

Causes To Personal / A Compelling Concept for 2025

Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable place as we start 2025. The corporate has two authorized merchandise producing revenues and a pipeline with a number of candidates in improvement. Its merchandise are produced and manufactured utilizing the ProCellEx platform which makes use of a plant cell line slightly than the standard mammalian one, to provide its therapeutic proteins. The corporate not too long ago eradicated all debt from its stability sheet and holds over $27 million in money on its stability sheet. We count on optimistic free money movement era over the subsequent 12 months, which ought to strengthen the stability sheet even additional.

The primary of its authorized merchandise is Elelyso, which was authorized in 2012 for Gaucher illness. Protalix signed commercialization agreements with Pfizer and Fiocruz, an arm of the Brazilian Ministry of Well being. This has led to annual gross sales from $16 to $23 million for the product worldwide. In Might 2023, Elfabrio was authorized by the FDA and EMA for Fabry illness. It is a $2 billion market dominated by three merchandise^[1] and one the place legacy choices current a number of shortcomings. Many sufferers develop antibodies towards the enzyme in Fabrazyme and Replagal which reduces its effectiveness. Galafold is barely acceptable for a subset of Fabry sufferers which have a sure galactosidase alpha gene (GLA) mutation. This creates a large opening for Elfabrio to step in and take market share within the underserved Fabry inhabitants.

In December, Protalix’ accomplice Chiesi submitted a Variation Software to the EMA that requested a change within the dosing routine for Elfabrio. Primarily based partly on the findings within the BRIGHT research and on new pharmacokinetic information, the sponsors are looking for a much less frequent dosing routine at a dose of two mg/kg physique weight administered each 4 weeks in grownup sufferers with Fabry illness within the European Union. Evaluation of the BRIGHT research concluded that therapy with Elfabrio each 4 weeks might provide a brand new therapy possibility for sufferers with Fabry illness.^[2]

Each Replagal and Fabrazyme are administered each two weeks, which equates to 26 administrations per yr. If Elfabrio had been in a position to achieve approval for administration each 4 weeks, this might scale back the variety of administrations relative to those older medicines by half to 13 infusions per yr. Elfabrio is a PEGylated,^[3] recombinant human α-Gal A. Because of PEGylation, Elfabrio is secure in plasma, beneath lysosome-like situations and presents a chronic plasma half-life in people of roughly 80 hours, in contrast with different commercially obtainable enzyme substitute therapies with half-lives of lower than two hours.

Different advantages of Elfabrio over friends is:

• Use of a plant-based expression system which keep away from most of the viral contamination issues confronted by mammalian cells;
• Fewer sufferers with anti-drug and neutralizing antibodies vs. Fabrazyme in BALANCE at finish of research;
• Discount in imply annualized estimated glomerular filtration price (eGFR) slope within the BRIDGE research;^[4]
• Potential for infusions each 4 weeks vs. each two weeks for Fabrazyme and Replagal.

Improvement Portfolio

Protalix’ improvement portfolio consists of two named merchandise and extra early-stage discovery applications. The named applications are PRX-115 in gout and PRX-119 for neutrophil extracellular traps (NETs) associated illnesses. PRX-115 has accomplished eight deliberate cohorts in a Part I research and preliminary outcomes have been introduced on the ACR Convergence convention. We focus on the main points of this system under.

PRX-115

In March 2023, Protalix introduced that it had dosed its first affected person within the Part I medical trial for PRX-115 within the therapy of extreme gout. Since then, Protalix has accomplished enrolling eight cohorts and has reported outcomes. The trial was designed as a single ascending dose, double-blinded, placebo-controlled research to look at security, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRX-115. 64 topics with elevated urate ranges (>6.0 mg/dL) acquired a single intravenous (IV) infusion divided amongst eight cohorts. Sufferers had been randomized in a 3:1 ratio between PRX-115 and placebo and had been monitored for 85 days (12 weeks) after receiving the infusion. Plasma concentrations of PRX-115 had been measured, as had been serum anti-drug antibodies and plasma urate ranges. A number of measurements had been taken all through the length of the research.

The research was performed at New Zealand Scientific Analysis beneath the New Zealand Medicines and Medical Units Security Authority. Additional particulars on the medical trial might be discovered on clinicaltrials.gov and the associated entry beneath Nct05745727.

Topics thought-about for enrollment introduced elevated uric acid ranges (>6.0 mg/dL) and no earlier publicity to PEGylated uricase. Major endpoints will consider the security and tolerability of a single infusion of PRX-115 as assessed by frequency of drug associated adversarial occasions, graded by severity. Scientific laboratory outcomes and very important indicators can even be evaluated. Secondary endpoints will look at the discount in uric acid and dosing efficacy.

Outcomes from the Part I PRX-115 trial had been introduced on the ACR annual assembly final November. The poster is entitled Extended Plasma Urate Reducing after a Single Intravenous Administration of PRX 115, a Novel PEGylated Uricase, in Members with Elevated Urate Ranges and was introduced by Protalix’ Dr. Orit Cohen Barak. PRX-115 was discovered to be well-tolerated. 25% of the topics handled (12/48) reported research drug associated adversarial occasions (AEs). One topic in cohort 2 skilled an anaphylactic response proper after infusion. The response resolved fully and the topic was evaluated over the course of the research for additional security assessments. No different topics skilled this response and there have been no different severe adversarial occasions.

Outcomes from the Part I help shifting on to the subsequent stage of improvement. Probably the most seen advantages of PRX-115 is that the product might enable for a discount within the variety of infusions required for profitable therapy in contrast with authorized merchandise. We be aware that Krystexxa which is authorized by the FDA and indicated for persistent gout is run each two weeks as an intravenous infusion. Planning for the PRX-115 Part II trial is underway with trial design particulars anticipated over the subsequent a number of quarters and a launch in 2H:25.

PRX-119

PRX-119 is the plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life within the circulation of the molecule for NETs-related illnesses. Protalix has performed preclinical research to guage the feasibility of the candidate and expects to proceed compiling preclinical data and conducting information evaluation to evaluation with stakeholders. Research performed up to now have decided that the administration of PRX-119 decreased circulating DNA ranges and considerably enhanced the survival of mice in each a CLP-induced sepsis mannequin and an ARDS mannequin. Extra preclinical improvement is ongoing. We count on to listen to additional particulars on the course of this system in coming quarters.

Causes to Personal

• Two globally authorized commercialized merchandise in uncommon illness
  
• Proprietary plant-based expression system
• Pipeline of merchandise together with lead PRX-115 in uncontrolled gout
  
• Free money movement producing
• Engaging valuation with goal value over 5x newest closing value
• No debt

Latest Protalix Analysis

• November 15, 2024
  
• August 22, 2024
  
• Might 15, 2024
  
• March 15, 2024
  
• November 7, 2023
  
• August 8, 2023
  
• Might 30, 2023
  
• Might 11, 2023
  
• Might 5, 2023
  

Abstract

Protalix maintains an enviable place within the small cap biotech area with a clear stability sheet holding no debt and anticipated optimistic free money era. The corporate options two authorized merchandise that we count on to develop and a improvement portfolio that has proven early success within the gout indication. The shares are considerably undervalued relative to our goal value. One of many major dangers within the small cap area is absent for Protalix, which is the necessity to increase capital and dilute earlier traders shifting the stability of traders in the direction of lengthy solely. We keep our valuation to $14 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to obtain our articles and stories emailed on to you every morning. Please go to our web site for added data on Zacks SCR.

DISCLOSURE: Zacks SCR has acquired compensation from the issuer immediately, from an funding supervisor, or from an investor relations consulting agency, engaged by the issuer, for offering analysis protection for a interval of a minimum of one yr. Analysis articles, as seen right here, are a part of the service Zacks SCR offers and Zacks SCR receives quarterly funds totaling a most payment of as much as $40,000 yearly for these companies offered to or concerning the issuer. Full Disclaimer HERE.

________________________

^{[1] Different merchandise embody Fabrazyme by Sanofi, Galafold by Amicus Therapeutics, and Replagal by Takeda. We depend on Consider, Ltd. for Fabry illness market measurement estimates.}

^{[2] Within the case, M., et al. A section III, open-label medical trial evaluating pegunigalsidase alfa administered each 4 weeks in adults with Fabry illness beforehand handled with different enzyme substitute therapies, Journal of Inherited Metabolic Illness. October 2024.}

^{[3] A pegylated drug is a therapeutic molecule that has been chemically modified by attaching polyethylene glycol (PEG) chains. The PEG coating primarily acts as a protecting protect, making the medication more practical and longer-lasting within the physique.}

^{[4] BRIDGE contributors improved from -5.90 mL/min/1.73m2/yr on Replagal to -1.19 mL/min/1.73m2/yr on Elfabrio in all sufferers.}